RNA Editing Is Having a Moment

Q4 Biochemistry, Genetics and Molecular Biology

Genetic Engineering & Biotechnology News Pub Date : 2023-11-01 DOI:10.1089/gen.43.11.13

Julianna LeMieux

引用次数: 0

Abstract

Genetic Engineering & Biotechnology NewsVol. 43, No. 11 Genome EditingRNA Editing Is Having a MomentAlthough DNA editing has been celebrated for its potential to create new drugs, a relatively unsung alternative, RNA editing, may end up stealing the showJulianna LeMieuxJulianna LeMieuxSearch for more papers by this authorPublished Online:9 Nov 2023https://doi.org/10.1089/gen.43.11.13AboutSectionsView articleView Full TextPDF/EPUB Permissions & CitationsPermissionsDownload CitationsTrack CitationsAdd to favorites Back To Publication ShareShare onFacebookTwitterLinked InRedditEmail View articleFiguresReferencesRelatedDetails Volume 43Issue 11Nov 2023 Information© 2023 by GEN PublishingTo cite this article:Julianna LeMieux.RNA Editing Is Having a Moment.Genetic Engineering & Biotechnology News.Nov 2023.36-38, 40.http://doi.org/10.1089/gen.43.11.13Published in Volume: 43 Issue 11: November 9, 2023PDF download

查看原文本刊更多论文

RNA编辑正在发挥作用

基因工程与生物技术新闻卷。【参考翻译】基因组编辑RNA编辑正在发挥作用尽管DNA编辑因其创造新药的潜力而备受赞誉，但另一种相对默默无闻的选择——RNA编辑，可能最终会偷了这篇文章Julianna LeMieuxJulianna lemieux搜索更多的论文作者出版在线:9十一月2023https://doi.org/10.1089/gen.43.11.13AboutSectionsView文章查看全文pdf /EPUB权限和CitationsPermissionsDownload CitationsTrack citations添加到收藏回到出版物ShareShare onFacebookTwitterLinked InRedditEmail查看文章figuresreferencesrelateddetails卷43Issue 11Nov 2023信息©2023 by GEN publishing引用这篇文章:JuliannaLeMieux。RNA编辑正在发挥作用。基因工程与生物技术新闻。2023年11月36- 38,40 .http://doi.org/10.1089/gen.43.11.13Published in Volume: 43 Issue 11: 11/11/2023 pdf下载

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Genetic Engineering & Biotechnology News 工程技术-生物工程与应用微生物

CiteScore

0.20

自引率

0.00%

发文量

210

审稿时长

3-6 weeks

期刊介绍： Genetic Engineering & Biotechnology News (GEN) is the flagship publication of Mary Ann Liebert, Inc. Launched in 1980, GEN was the first publication in this field and remains the key driver in the explosion of the industry, paving the way for the development of new technologies and applications, investment growth, and career opportunities. With nearly 40 years of publishing experience, GEN maintains unrivaled integrity, influence, and expertise that plays a pivotal role in driving the productivity and growth of the industry. Through its cornerstone Magazine, high-frequency newsletters, and dynamic suite of multimedia resources, GEN is the 360-degree resource that researchers and executives depend on for information that is pivotal for their organization’s success. GEN’s breadth of editorial coverage is unrivaled in the industry, providing exclusive coverage of the entire bioproduct lifecycle across five key pillars: Drug Discovery, Bioprocessing, OMICS, Translational Medicine, and Gene Editing.